英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

priorite    
钇易解石

钇易解石


请选择你想看的字典辞典：
单词字典翻译
priorite查看　priorite　在百度字典中的解释百度英翻中〔查看〕
priorite查看　priorite　在Google字典中的解释Google英翻中〔查看〕
priorite查看　priorite　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • General Clinical Practice Use of Nadofaragene Firadenovec . . .
    Practical Considerations for Nadofaragene Firadenovec Use e firadenovec, including administration, monitoring, supportive care, and patient education Successful instillation of nadofaragene fir denovec requires understanding its transportation, storage, and administration requirements While urolo-gy clinics and ealth car Figure 1
  • Package Insert and Information for Patients - Adstiladrin
    11 DESCRIPTION ADSTILADRIN (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy for intravesical instillation
  • ADSTILADRIN | FDA - U. S. Food and Drug Administration
    STN: BLA 125700 Proper Name: nadofaragene firadenovec-vncg Tradename: ADSTILADRIN Manufacturer: Ferring Pharmaceuticals A S Indication: High-grade, Bacillus Calmette-Guerin (BCG) unresponsive non
  • Nadofaragene Firadenovec-vncg Monograph for Professionals . . .
    After the instillation, allow nadofaragene firadenovec-vncg to be left in the bladder for 1 hour During the 1 hour dwell time, the patient should reposition approximately every 15 minutes See Full Prescribing information for additional instructions on preparation and administration of nadofaragene firadenovec-vncg
  • Dosing | ADSTILADRIN® (nadofaragene firadenovec-vncg)
    Find information on the dosing and administration of ADSTILADRIN®, including instillation details See Important Safety Info
  • ADSTILADRIN® (nadofaragene firadenovec-vncg) | For HCP
    Nadofaragene firadenovec- vncg (ADSTILADRIN) is A recommended treatment option: In the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)* and the AUA SUO Guidelines1 By the International Bladder Cancer Group (IBCG) for high-risk NMIBC after BCG failure for those seeking to avoid radical cystectomy 2
  • Adstiladrin: Package Insert Prescribing Information MOA
    ADSTILADRIN (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy for intravesical instillation It is a recombinant adenovirus serotype 5 vector containing a transgene encoding the human interferon alfa-2b (IFNα2b)
  • Package Insert - ADSTILADRIN
    11 DESCRIPTION ADSTILADRIN (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy for intravesical instillation It is a recombinant adenovirus serotype 5 vector containing a transgene encoding the human interferon alfa-2b (IFNα2b) ADSTILADRIN has a nominal concentration of 3 x 1011 vp mL
  • Nadofaragene firadenovec-vncg (urinary bladder route)
    Description Nadofaragene Firadenovec-vncg is used to treat patients with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with a tumor type called carcinoma in situ (CIS) with or without papillary tumors This medicine is to be used only by or under the direct supervision of a doctor
  • Adstiladrin | European Medicines Agency (EMA)
    Nadofaragene firadenovec is a non-replicating, recombinant type 5 adenovirus vector-based gene therapy containing the human IFNα2b transgene Its intravesical administration results in the entry of viral particles into the tumour cells and the urothelium of the bladder, leading to the expression of the IFNα2b protein in such cells, which in





中文字典-英文字典  2005-2009